ANI Pharmaceuticals (ANIP)

[rgshredder]

Fenofibrate is a Solvay product owned by AbbVie in the states and Mylan outside the US. There’s a few brand names deviating by differing doses/formulations: Tricor by AbbVie, Lofibra by Teva, Supralip by Abbott Labs to name a few, and all alongside their generic counterparts.

The drug class itself serves to lower cholesterol as its primary labeled use, but can independently reduce disability and death from atherosclerotic cardiovascular disease and stroke.

It has been shown in previous studies to carry an antiviral efficacy in patients with hep C. The idea is that the drug lowers plasma fibrinogen (coagulation factor involved in clotting blood) levels reducing the hypercoagulable state that is often seen in COVID-19 patients as a secondary consequence (and often the inciting cause of death) as their symptoms/disease state progresses due to their heightened inflammatory response.

When the news article was released (as of this point, a pubmed search doesn’t show the scientific article yet (or at least I can’t find it)), none of the aforementioned companies saw any changes to volume/share price in reaction to it. I’d suspect AbbVie would have at the least given they used Tricor specifically (from what I understood), and although they've recently hit a two year high in share price, I couldn't find any specific articles linking that success to this particular study.

With the overly enthusiastic response on share price whenever a possible COVID-19 treatment is even whispered in public, really surprised this study/information isn't influencing those companies who had already invested in this possible treatment.

RG